Lv5
988 积分 2026-02-02 加入
Efficacy and safety of hepatic arterial infusion chemotherapy combined with donafenib in the treatment of unresectable hepatocellular carcinoma
2天前
已完结
Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
17天前
已完结
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma
19天前
已完结
Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress
19天前
已完结
Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression
20天前
已完结
SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer
23天前
已完结
Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment
24天前
已完结
Liver injury related to vascular endothelial growth factor tyrosine kinase inhibitors: a pharmacovigilance analysis of the USA FDA adverse event reporting system (FAERS) database
24天前
已完结
Toxic epidermal necrolysis attributed to cabozantinib monotherapy: first reported case
1个月前
已完结
The association between anti-acid use and tyrosine kinase inhibitor-induced hepatotoxicity
1个月前
已完结
皖公网安备34019202002308
